Osivax CEO Hopes Vaccines Maker Can Develop Universal Flu ‘Silver Bullet’
Executive Summary
Emerging Company Profile: Osivax is using its oligoDOM technology platform to developer a vaccine pipeline. The French biotech aims to establish proof-of-concept in influenza A then expand the pipeline to provide a universal flu vaccine.
You may also be interested in...
Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
AstraZeneca Pledges To Become Carbon-Negative By 2030
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.
Novo Executive Calls For ‘Real AMR Action’ In Davos
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
Need a specific report? 1000+ reports available
Buy Reports